Weir Science plans launch of non-hormonal 'Viagra for women' targeting menopausal sexual health

A groundbreaking non-hormonal drug called Myregyna, dubbed the 'Viagra for women,' is set to launch, aiming to improve sexual response and function in women over 50, especially those experiencing menopause. Invented by New Zealand cell biologist Dr. Iona Weir, the plant-based cream has been proven in clinical trials to boost natural hydration and reverse symptoms of Genitourinary Syndrome of Menopause (GSM), which causes vaginal dryness, discomfort, and pain during sex. The cream, applied nightly alongside a daily supplement, offers a hormone-free alternative that supports genital health and aims to restore women's sex lives and overall vitality. Dr. Weir's company, Weir Science, expects sales to exceed £7.5 billion annually, reflecting significant global demand, and is currently negotiating with major pharmaceutical companies while registering the product with the US Food and Drug Administration. Women who participated in trials reported significant improvements, including resuming regular sexual activity without pain, highlighting the drug's transformative potential beyond just sexual benefits. This innovation addresses a long-neglected issue in women's health, providing a much-needed counterpart to male erectile dysfunction treatments like Viagra.